ALGS Stock - Aligos Therapeutics, Inc.
Unlock GoAI Insights for ALGS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.94M | $15.53M | $13.91M | $4.36M | N/A |
| Gross Profit | $3.94M | $15.53M | $13.91M | $4.36M | $-3,325,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | N/A |
| Operating Income | $-89,154,000 | $-88,127,000 | $-97,580,000 | $-128,321,000 | $-97,834,000 |
| Net Income | $-131,211,000 | $-87,679,000 | $-96,046,000 | $-128,332,000 | $-108,543,000 |
| Net Margin | -3326.0% | -564.6% | -690.6% | -2944.1% | N/A |
| EPS | $-20.94 | $-3.52 | $-2.25 | $-3.22 | $-3.18 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 18th 2025 | H.C. Wainwright | Resumed | Buy | $50 |
| August 19th 2024 | H.C. Wainwright | Initiation | Buy | $75 |
| January 6th 2023 | Piper Sandler | Upgrade | Overweight | $3← $2 |
| January 6th 2023 | Jefferies | Upgrade | Buy | $3← $2.5 |
Earnings History & Surprises
ALGSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 9, 2026 | $-2.09 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-2.09 | $-3.04 | -45.5% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-2.35 | $-1.53 | +34.9% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-2.80 | $-2.11 | +24.6% | ✓ BEAT |
Q1 2025 | Mar 10, 2025 | $-2.63 | $-3.41 | -29.7% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-2.15 | $-3.07 | -42.8% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-4.00 | $0.75 | +118.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-4.75 | $-5.50 | -15.8% | ✗ MISS |
Q1 2024 | Mar 12, 2024 | $-6.75 | $-5.50 | +18.5% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-12.00 | $-10.25 | +14.6% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-12.50 | $-10.75 | +14.0% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-12.25 | $-13.25 | -8.2% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-12.25 | $-12.75 | -4.1% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-14.25 | $-11.00 | +22.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-16.25 | $-11.75 | +27.7% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-16.50 | $-21.00 | -27.3% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-20.75 | $-22.25 | -7.2% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-20.75 | $-19.50 | +6.0% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-20.25 | $-19.75 | +2.5% | ✓ BEAT |
Q2 2021 | May 10, 2021 | $-22.50 | $-18.50 | +17.8% | ✓ BEAT |
Latest News
Aligos Therapeutics Announces Data From Four Presentations, Including Two Oral Presentations, At HEP-DART 2025 Meeting
📈 PositiveAligos Therapeutics shares are trading lower after the company reported worse-than-expected Q3 EPS results.
📉 NegativeAligos Therapeutics Q3 EPS $(3.04) Misses $(2.27) Estimate, Sales $741.000K Beat $500.000K Estimate
➖ NeutralAligos Therapeutics Says USAN Council Adopts Pevifoscorvir Sodium As Generic Name For ALG-000184, Under Investigation For Treatment Of Chronic Hepatitis B Virus Infection
➖ NeutralHC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target
📈 PositiveAligos Therapeutics shares are trading higher after HC Wainwright & Co. assumed a Buy rating on the stock and announced a price target of $50.
📈 PositiveHC Wainwright & Co. Assumes Aligos Therapeutics at Buy, Announces Price Target of $50
📈 PositiveFrequently Asked Questions about ALGS
What is ALGS's current stock price?
What is the analyst price target for ALGS?
What sector is Aligos Therapeutics, Inc. in?
What is ALGS's market cap?
Does ALGS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ALGS for comparison